BioCardia CEO buys 7,500 shares in open market

BioCardia, Inc. President and CEO Peter Altman reported a series of open‑market purchases of common stock.

Accepted by SEC EDGAR 07/10/2026 - 06:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported a series of open‑market purchases of common stock. On July 8–10, 2026, he bought a total of 7,500 shares in three transactions, including 5,500 shares at $0.97, 1,000 shares at $0.90, and 1,000 shares at $0.94 per share. After these purchases, he directly owns 369,485 common shares. A footnote states that one transaction was executed in multiple trades between $0.92 and $1.05 per share and that the reported price is a weighted average, with full trade‑level details available upon request.

Insider Trade Summary

Net Buyer: 7,500 shares

Net Buy 3 txns

Insider Altman Peter

Role President and CEO

Bought 7,500 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,000	$0.94	$940.00
Purchase	Common Stock	1,000	$0.90	$900.00
Purchase	Common Stock F1	5,500	$0.97	$5K

Holdings After Transaction: Common Stock — 369,485 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades ranging from $0.92 to $1.05 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased July 8, 2026: 5,500 shares at $0.9700 Shares purchased July 9, 2026: 1,000 shares at $0.9000 Shares purchased July 10, 2026: 1,000 shares at $0.9400 +3 more

6 metrics

Shares purchased July 8, 2026 5,500 shares at $0.9700 Open-market purchase of common stock on 2026-07-08

Shares purchased July 9, 2026 1,000 shares at $0.9000 Open-market purchase of common stock on 2026-07-09

Shares purchased July 10, 2026 1,000 shares at $0.9400 Open-market purchase of common stock on 2026-07-10

Total shares purchased 7,500 shares Sum of three open-market purchases reported in this Form 4

Shares owned after latest transaction 369,485 shares Direct ownership of BioCardia common stock following July 10, 2026 purchase

Price range for multiple trades $0.92–$1.05 per share Footnote range for executions within one reported transaction, weighted average price shown

Key Terms

open-market purchase, weighted average, beneficial ownership

3 terms

open-market purchase financial

"reported a series of open‑market purchases of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average financial

"reported price is a weighted average, with full trade‑level details"

A weighted average is a way of calculating an overall number when some items matter more than others by giving each item a different level of importance, or weight. Investors use weighted averages to combine figures like prices, returns or earnings so the result reflects the size or significance of each part — like grading a class where a final exam counts more than a quiz, producing a score that better represents true performance.

beneficial ownership financial

"details available upon request to the SEC staff, the issuer or security holder"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) CEO Peter Altman report in this Form 4?

Peter Altman reported open‑market purchases of 7,500 BioCardia common shares over three days in July 2026, increasing his direct ownership to 369,485 shares.

How many BioCardia (BCDA) shares did the CEO buy and on which dates?

Peter Altman bought 7,500 BioCardia shares in total: 5,500 shares on July 8, 2026, 1,000 shares on July 9, 2026, and 1,000 shares on July 10, 2026.

At what prices did BioCardia (BCDA) CEO Peter Altman purchase shares?

He purchased shares at $0.97 per share (5,500 shares), $0.90 per share (1,000 shares), and $0.94 per share (1,000 shares). A footnote notes multiple trades between $0.92 and $1.05 for one transaction.

What is Peter Altman’s total BioCardia (BCDA) shareholding after these transactions?

Following the reported purchases, Peter Altman directly owns 369,485 shares of BioCardia common stock, as disclosed in the post‑transaction ownership figures in the filing.

What does the weighted average price footnote mean in the BioCardia (BCDA) Form 4?

The footnote explains that one transaction involved multiple trades between $0.92 and $1.05 per share and that the reported price is a weighted average, with full trade‑level details available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		P		5,500(1)	A	$0.97(1)	367,485	D
Common Stock	07/09/2026		P		1,000	A	$0.9	368,485	D
Common Stock	07/10/2026		P		1,000	A	$0.94	369,485	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.92 to $1.05 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)